基于重组酵母的亚单位疫苗单剂接种可抵抗甲型流感病毒感染
研究报告基于乳酸克鲁维酵母(K. lactis)重组酵母的亚单位疫苗,表达流感血凝素(HA)单独或联合M1基质蛋白。灭活未处理酵母材料皮下接种BALB/c小鼠,在初免/加强和单剂方案下均完全保护免受致死性同源流感病毒攻击,诱导的中和抗体滴度与灭活病毒疫苗相当。
要点
- 重组K. lactis酵母表达的HA±M1亚单位疫苗可完全保护小鼠抵抗致死性流感攻击。
- 单剂接种方案即达完全保护,中和抗体滴度与灭活病毒疫苗相当。
- 该平台有望开发多价、DIVA兼容的兽用流感疫苗替代传统病毒疫苗。
核心结论
- 基于重组K. lactis酵母的HA±M1亚单位疫苗在初免/加强及单剂方案下均完全保护BALB/c小鼠抵抗致死性同源甲型流感病毒攻击,中和抗体滴度与灭活病毒疫苗相当。
研究设计与样本
- 研究使用可快速生成转基因酵母的遗传系统构建表达流感HA单独或联合M1的K. lactis菌株,以灭活未处理酵母材料皮下接种BALB/c小鼠,采用初免/加强及单剂方案,随后以同源致死性流感病毒攻击。
主要发现
- 灭活未处理酵母材料皮下接种在初免/加强和单剂方案下均完全保护BALB/c小鼠抵抗后续同源致死性流感病毒攻击。
- 酵母疫苗诱导的中和抗体滴度与灭活病毒疫苗诱导的滴度相当。
- 数据提示HA和M1在酵母细胞中高抗原性表达。
临床怎么用
- 该酵母亚单位疫苗平台可作为传统病毒基抗流感疫苗的有前景替代,面向兽用多价、DIVA兼容疫苗开发。
局限性
- 证据仅来自BALB/c小鼠模型,未报告人体或靶动物数据。
- 保护仅针对同源病毒攻击,未评估异源亚型交叉保护。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Here we report on new subunit vaccines based on recombinant yeast of the type Kluyveromyces lactis (K. lactis), which protect mice from a lethal influenza A virus infection. Applying a genetic system that enables the rapid generation of transgenic yeast, we have developed K. lactis strains that express the influenza A virus hemagglutinin, HA, either individually or in combination with the viral M1 matrix protein. Subcutaneous application of the inactivated, but otherwise non-processed yeast material shows a complete protection of BALB/c mice in prime/boost and even one-shot/single dose vaccination schemes against a subsequent, lethal challenge with the cognate influenza virus. The yeast vaccines induce titers of neutralizing antibodies that are readily comparable to those induced by an inactivated virus vaccine. These data suggest that HA and M1 are produced with a high antigenicity in the yeast cells. Based on these findings, multivalent, DIVA-capable, yeast-based subunit vaccines may be developed as promising alternatives to conventional virus-based anti-flu vaccines for veterinary applications.
引用
- Gebauer M, Hürlimann HC, Behrens M, et al. Subunit vaccines based on recombinant yeast protect against influenza A virus in a one-shot vaccination scheme. Vaccine. 2019. PMID: 31399274. doi:10.1016/j.vaccine.2019.07.094
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。